Researchers have discovered that a protein called cardiotrophin 1 (CT1) can trick the heart into growing in a healthy way and pumping more blood, just as it does in response to exercise and pregnancy. They show that this good kind of heart growth is very different from the harmful enlargement of the heart that occurs during heart failure. They also show that CT1 can repair heart damage and improve blood flow in animal models of heart failure.
The results are published in Cell Research. The research team is from The Ottawa Hospital, the University of Ottawa, the University of Ottawa Heart Institute and Carleton University.
Heart failure is a leading cause of death and disability in high-income countries and a growing problem around the world. It occurs when the heart can’t pump enough blood through the body, often because a heart attack has damaged the heart muscle tissue.
“When part of the heart dies, the remaining muscles try to adapt by getting bigger, but this happens in a dysfunctional way and it doesn’t actually help the heart pump more blood,” said Dr. Lynn Megeney, senior author of the study and a senior scientist at The Ottawa Hospital and professor at the University of Ottawa. “We found that CT1 causes heart muscles to grow in a more healthy way and it also stimulates blood vessel growth in the heart. This actually increases the heart’s ability to pump blood, just like what you would see with exercise and pregnancy.”
Dr. Megeney and his colleagues conducted a variety of studies in mice, rats and cells growing in the lab. In addition to CT-1, some of the studies involved a drug called phenylephrine (PE), which is known to cause the bad kind of heart growth. They found:
• Heart muscle cells treated with CT-1 become longer, healthier fibres, while those treated with PE just grow wider.
• CT-1 causes blood vessels to grow alongside the new heart muscle tissue and increases the heart’s ability to pump blood, while PE does neither.
• When CT-1 treatment stops, the heart goes back to its original condition, just like it does when exercise or pregnancy end. However, the dysfunctional heart growth caused by PE is irreversible.
• CT-1 dramatically improves heart function in two animal models of heart failure – one caused by a heart attack (affecting the left side of the heart) and one caused by high blood pressure in the lungs (pulmonary hypertension, affecting the right side of the heart).
• Both CT-1 and PE stimulate heart muscle growth through a molecular pathway that has traditionally been associated with promoting cell suicide (apoptosis), but CT-1 has a better ability to control this pathway.
“This experimental therapy is very exciting, particularly because it shows promise in treating both left and right heart failure,” said Dr. Duncan Stewart, a cardiologist, senior scientist and co-senior author on the paper who is also Executive Vice-President of Research at The Ottawa Hospital and a professor at the University of Ottawa. “Currently, the only treatment for right heart failure is a transplant. And although we have drugs that can reduce the symptoms of left heart failure, we can’t fix the problem, and left heart failure often leads to right heart failure over time.”
“An intriguing aspect of this research was how human CT1 was able to promote a healthy growth response in multiple animal models,” said co-author Dr. Patrick Burgon, scientist at the University of Ottawa Heart Institute and assistant professor at the University of Ottawa. “This suggests the action of CT1 is universally conserved and puts us much closer to therapy.”
The researchers also note that while exercise could theoretically have the same benefits as CT-1, people with heart failure are usually limited in their ability to exercise.
Dr. Megeney and Dr. Stewart have patents pending for the use of CT-1 to treat heart conditions and they hope to develop partnerships to test this protein in patients. If this testing is successful it will take a number of years for the treatment to become widely available.
The Latest on: Heart failure
- Minority heart failure patients may get less access to specialized ICUson October 29, 2019 at 2:58 pm
(Reuters Health) - Heart failure patients who are black, Hispanic or female are less likely than others to be admitted to specialized cardiac units, a disparity that may help explain long-known racial ...
- Not All Heart Failure Patients Get Same Level of Care, Study Findson October 29, 2019 at 12:04 pm
Not All Heart Failure Patients Get Same Level of Care, Study Finds By Robert Preidt, HealthDay Reporter TUESDAY, Oct. 29, 2019 (HealthDay News) -- If you are black or Hispanic and you are hospitalized ...
- Telehealth effectively diagnoses/manages fetal congenital heart disease in rural patientson October 29, 2019 at 8:54 am
A recent study of 368 pregnant mothers, led by Bettina Cuneo, MD, director of perinatal cardiology and fetal cardiac telemedicine at Children's Hospital Colorado, found that fetal congenital heart ...
- Race may play a role in heart failure treatmenton October 29, 2019 at 8:30 am
Oct. 29 (UPI) --For heart failure patients, skin color may play a role in the quality of care they receive, a new study suggests. In an analysis published Tuesday in the journal Circulation: Heart ...
- An avocado a day could lower your 'bad' cholesterol levels and reduce your risk of heart diseaseon October 29, 2019 at 6:25 am
"Bad" cholesterol means LDL (low-density lipoprotein), and having too much can clot arteries and lead to heart problems.
- Mom Takes On NYC Marathon for Son With Heart Disease Who Won’t Be Able to Run Oneon October 29, 2019 at 5:16 am
Two weeks later, Zachary was brought in for a heart check-up on Christmas Eve. To the surprise of his parents, the doctors diagnosed him with heart valve disease—a congenital heart defect that can ...
- Valvular Heart Disease Treatment Market 2019: Business overview, Industry insights, Trends and Top Company Analysis Forecast by 2026on October 29, 2019 at 4:15 am
Oct 29, 2019 (Market Insight Reports via COMTEX) -- The research report published by Verified Market Research is a comprehensive study of the global Valvular Heart Disease Treatment Market. The ...
- Study finds inequities in access to heart failure careon October 29, 2019 at 2:03 am
Nationally, heart failure patients who receive specialized cardiology care after admission tend to have better outcomes, including lower readmission rates and lower rates of death. But not all ...
- Intermountain Healthcare sending 'golden tickets' to participants for heart disease studyon October 28, 2019 at 5:17 pm
Researchers announced Monday at the Intermountain Gardner Transformation Center that they are expanding a study that could better identify patients with heart disease. Teran had been chosen for the ...
- MyoKardia's MYK-491 shows positive effect in certain heart failure patientson October 28, 2019 at 11:03 am
MyoKardia (MYOK-0.5%) announces positive preliminary data from a Phase 2a clinical trial evaluating MYK-491 in patients with stable heart failure due to the inability of the left ventricle to pump ...
via Google News and Bing News